Prosensa BV, a Dutch developer of RNA-based therapeutics, has raised €18 million in Series B funding. GIMV and AGF Management co-led the round, and were joined by return backers Abingworth Management, Life Sciences Partners and MedSciences Capital. www.prosensa.eu